Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.

Journal of neuro-oncology - 8 Jun 2026

Lanman Tyler A, Gonzalez Castro L Nicolas, Perlow Haley K, Youssef Gilbert, Strowd Roy E, Milano Michael T, Kushnirsky Marina, Bhatia Ankush, Wen Patrick Y, Miller Julie J, Rich Benjamin J

Abstract excerpt

PURPOSE: IDH-mutant glioma management has been rapidly evolving following the 2024 FDA approval of the mutant IDH inhibitor (IDHi), vorasidenib. However, optimal treatment decisions for many specific scenarios remain unclear. The aim of this study was to provide insight into how clinicians collectively approach different clinical scenarios and evaluate how demographic and professional backgrounds influence...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Glioma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Practice Patterns, Physicians'

Share to Surveys and Questionnaires

Source

Open in PubMed Open full text

Identifiers

PMID: 42258073
DOI: 10.1007/s11060-026-05630-3
PMCID: PMC13246546

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contemporary practice patterns in IDH-mutant glioma management: a multidisciplinary multi-institutional survey.PMID 42258073Read ↗

Multidisciplinary consensus recommendations for the management of IDH-mutant grade 2 gliomas in Spain: a Delphi study.Semantic proximity Read ↗

Clinical outcomes and management of CDKN2A/B homozygously deleted IDH-mutant astrocytomas—a cohort study and patterns of care surveySemantic proximity Read ↗

The Role of Mutant IDH Inhibitors in the Treatment of Glioma.Semantic proximity Read ↗

Changes in clinical management of diffuse IDH-mutated lower-grade gliomas: patterns of care in a 15-year period.Semantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Treatment Options for IDH-Mutant Malignant Gliomas.Semantic proximity Read ↗

Targeted Options for Glioma Looking Good.Semantic proximity Read ↗

Incidence and Survival of IDH-Wildtype Glioblastoma and IDH-Mutant Astrocytoma by Treatment and Sex: A Regional Study in Spain (2011-2021).Semantic proximity Read ↗

Real-world clinical practice patterns in the surgical management of low-grade astrocytomas: An analysis of Surveillance, Epidemiology, and End Results (SEER) and the National Cancer Database (NCDB) databasesSemantic proximity Read ↗

Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaSemantic proximity Read ↗

Impact of tissue-agnostic approvals on management of primary brain tumors.Semantic proximity Read ↗

Molecular matched targeted therapies for primary brain tumors-a single center retrospective analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.